New pill for advanced cancers enters first human tests
NCT ID NCT07482592
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new oral drug, TQB3205, in 156 adults with advanced malignant tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also looking for any signs that the drug shrinks tumors. Participants take the capsule by mouth and are closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.